"Similar trends" that fell short of statistical significance were also seen when JAK inhibitors were compared with less popular types of biologic therapy, such as interleukin (IL)-6 inhibitors ...

Janus kinase (JAK) inhibitors are an important treatment option ... increased risk of cardiovascular diseases and certain ...

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, pote Incyte is preparing to ...

The use of JAK vs TNF inhibitors shows no significant increase in the incidence of major adverse cardiovascular events in ...

A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk ...

TIAs seemed to drive the increased MACE rates for anti-TNFs and other biologics versus JAK inhibitors. No difference in rates of stroke were seen among the three drug types, and MIs were only ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

Citation: JAK inhibitors show no increased cardiovascular risk in rheumatoid arthritis patients, large international study finds (2025, April 30) retrieved 3 May 2025 from https://medicalxpress ...

New study links prior VTE, diabetes, recent hospitalization, and JAK inhibitor use with elevated thromboembolism risk in ...

Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors ... IL-23, and type I interferons, thereby clinically improving psoriatic plaques.

Janus kinase (JAK) inhibitors led to improvement of uveitis in approximately half of pediatric patients previously treated with disease-modifying antirheumatic drugs (DMARDs) in a case series.

During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.